NCT00965809

Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD)

Double Blind, Placebo-Controlled Trial of THC as add-on Therapy for PTSD

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: Hadassah Medical Organization · Academic / Other
• Sex: All
• Age: 19 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Stress Disorder (PTSD) is a chronic and debilitating anxiety disorder which is widespread in every social level and is very prevalent in outpatient and inpatient settings. A recent open-label study showed that the synthetic cannabinoid receptor agonist Nabilone had beneficial effects abolishing or greatly reducing nightmares that persisted in spite of treatment with conventional PTSD medications. Furthermore, a big number of patients suffering from chronic PTSD report using smoked marijuana because its tranquilizing effect and sleep quality improvement. According to clinical and epidemiological data different derivates from the cannabis plant are illegally and pervasively consumed by PTSD patients in order to reduce distress. The aim of the proposed study is to broaden the previous observations and to measure the extent to which Δ 9-THC will bring to significant improvement on the full spectrum of PTSD symptoms.

Conditions

• Posttraumatic Stress Disorders

Interventions

Type	Name	Description
DRUG	Tetrahydrocannabinol	Five mg. of THC in 6 drops of olive oil orally twice a day for 6 weeks.
OTHER	Placebo	Subjects will take 6 drops of olive oil orally twice a day from an identical vial than those in the active arm

Timeline

• Start date: 2009-10-01
• Primary completion: 2012-10-01
• Completion: 2013-04-01
• First posted: 2009-08-26
• Last updated: 2012-10-30

Locations

1 site across 1 country: Israel